CoDa Therapeutics, a San Diego biotechnology company focused on therapies for treating wounds, said Oct. 6 that it obtained a $6 million term loan from Square 1 Bank.

The new financing comes on the heels of the company’s announcement in April that it raised $19 million in Series B venture capital investment.

The company said it is pioneering a new field of science called gap junction modulation that uses a new class of therapeutics that can modulate wound responses and reduce inflammation.

— Mike Allen